ATHX Athersys Inc.

+0.02  (+1%)
Previous Close 1.53
Open 1.54
Price To Book 5.34
Market Cap 227606245
Shares 146,842,739
Volume 549,871
Short Ratio
Av. Daily Volume 579,880

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 enrollment commenced November 2017 (Japan).
Multistem - TREASURE (Japan)
Ischemic stroke
Phase 3 MASTERS-2 trial initiation announced July 31, 2018.
Ischemic stroke
Phase 2 enrollment continues but reported May 2018 that enrollment is slower than expected.
Acute myocardial infarction
Phase 2a data released January 23, 2019.
Acute Respiratory Distress Syndrome

Latest News

  1. What Makes Athersys (ATHX) a New Buy Stock
  2. Athersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript
  3. Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
  4. Athersys, Inc. to Host Earnings Call
  5. Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
  6. Is Athersys, Inc.’s (NASDAQ:ATHX) CEO Paid Enough Relative To Peers?
  7. Athersys to Host Year-End 2018 Financial Results Call
  8. Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
  9. Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?
  10. Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)
  11. Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
  12. Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT
  13. Are Athersys Inc’s (NASDAQ:ATHX) Interest Costs Too High?
  14. Athersys Reports Third Quarter 2018 Results
  15. Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
  16. Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
  17. Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
  18. Global Stem Cell Market Expected to Reach $270.5 Billion